Lilly Waiting On Phase III Data For Donanemab

 
• By Joseph Haas
  
Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Lilly hopes confirmatory Phase III data will change CMS's view on amyloid-lowering drugs
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business